Hepion Pharmaceuticals, Inc. (HEPA)
NASDAQ: HEPA · IEX Real-Time Price · USD
2.490
-0.010 (-0.40%)
At close: Mar 28, 2024, 4:00 PM
2.520
+0.030 (1.20%)
After-hours: Mar 28, 2024, 6:35 PM EDT

Hepion Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 202220212020201920182017201620152014
Cash & Equivalents
51.1991.3540.7313.922.835.957.44.561.82
Cash & Cash Equivalents
51.1991.3540.7313.922.835.957.44.561.82
Cash Growth
-43.96%124.30%192.52%391.56%-52.43%-19.58%62.25%151.03%-
Other Current Assets
5.316.11.910.470.140.110.490.680.16
Total Current Assets
56.597.4542.6314.392.976.067.895.241.98
Property, Plant & Equipment
0.130.460.660.860.030.060.080.080.01
Goodwill and Intangibles
01.871.871.871.871.871.8700
Other Long-Term Assets
3.623.773.483.53.323.263.260.050
Total Long-Term Assets
3.756.16.016.225.225.195.210.130.02
Total Assets
60.24103.5548.6520.618.1911.2513.115.382
Accounts Payable
2.672.453.720.490.751.564.251.480.25
Current Debt
0.050.270.280.271.4400.0100
Other Current Liabilities
5.175.490.660.850.661.050.820.460.21
Total Current Liabilities
7.898.214.661.612.852.65.081.940.46
Long-Term Debt
00.050.470.5400000
Other Long-Term Liabilities
2.52.32.992.843.364.956.7104.48
Total Long-Term Liabilities
2.52.353.463.393.364.956.7104.48
Total Liabilities
10.3910.568.124.996.217.5511.791.944.93
Total Debt
0.050.320.750.811.4400.0100
Debt Growth
-83.09%-57.86%-6.85%-43.93%-----
Retained Earnings
-175.7-133.5-104.11-83.75-76.46-67.01-44.61-27.61-5.42
Comprehensive Income
-0.0900000000
Shareholders' Equity
49.869340.5215.621.983.71.323.44-2.93
Net Cash / Debt
51.1491.0339.9713.121.395.957.394.561.82
Net Cash / Debt Growth
-43.83%127.72%204.79%841.92%-76.61%-19.47%62.03%151.03%-
Net Cash Per Share
13.4225.9082.61128.38151.45861.283060.242349.721588.95
Working Capital
48.6189.2537.9712.780.123.462.813.311.52
Book Value Per Share
13.0826.4683.74152.86214.82535.67545.331770.56-2562.94
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).